CHF

CHF
Name	Congestive heart failure
Field	Cardiology
Symptoms	Dyspnea, fatigue, edema
Complications	Arrhythmia, renal dysfunction, hepatic congestion
Onset	Acute or chronic
Causes	Ischemic heart disease, hypertension, valvular disease, cardiomyopathy
Diagnosis	Clinical assessment, echocardiography, natriuretic peptides
Treatment	Pharmacotherapy, device therapy, lifestyle modification, transplantation
Medication	ACE inhibitors, ARBs, beta-blockers, diuretics, mineralocorticoid receptor antagonists

CHF

Introduction

Congestive heart failure is a clinical syndrome characterized by impaired cardiac output and/or elevated intracardiac pressures leading to perfusion deficits and congestion. It arises from diverse cardiac insults and interacts with comorbid conditions to produce symptoms such as breathlessness, fatigue, and fluid retention. Management integrates pharmacologic therapies, device-based interventions, and advanced therapies within multidisciplinary programs.

Signs and Symptoms

Patients commonly present with exertional dyspnea, orthopnea, paroxysmal nocturnal dyspnea, peripheral edema, and fatigue. On examination one may find jugular venous distension, pulmonary rales, displaced apical impulse, S3 gallop, and hepatomegaly. Worsening cases evolve acute pulmonary edema or cardiogenic shock requiring urgent care.

Causes and Pathophysiology

Major etiologies include ischemic heart disease from coronary artery atherosclerosis, longstanding arterial hypertension often related to hypertensive heart disease, valvular disorders such as degenerative aortic stenosis and mitral regurgitation, and primary cardiomyopathies including dilated and hypertrophic forms. Additional contributors encompass myocarditis after infectious syndromes, tachyarrhythmia-mediated cardiomyopathy, toxin exposure (for example alcohol or anthracyclines), and metabolic diseases such as diabetes mellitus and thyroid disorders. Pathophysiology hinges on myocardial injury causing reduced contractility or impaired relaxation, neurohormonal activation of the renin–angiotensin–aldosterone system and sympathetic nervous system, ventricular remodeling, and progressive renal and hepatic congestion that exacerbate volume overload.

Diagnosis

Diagnosis combines history, physical examination, laboratory testing, and imaging. Measurement of natriuretic peptides aids distinction from noncardiac dyspnea. Electrocardiography identifies ischemia, conduction disease, or arrhythmias; chest radiography demonstrates cardiomegaly and pulmonary congestion. Transthoracic echocardiography quantifies left ventricular ejection fraction, chamber dimensions, valvular lesions, and diastolic function. Cardiac catheterization evaluates coronary anatomy when ischemia is suspected, while cardiac magnetic resonance imaging characterizes myocarditis, infiltrative diseases, and fibrosis. Exercise testing and cardiopulmonary exercise testing assist risk stratification for advanced therapies.

Management and Treatment

Initial stabilization of acute decompensation emphasizes oxygenation, diuretics for volume removal, vasodilators for afterload reduction, and inotropes for hypoperfusion when indicated. Guideline-directed medical therapy for systolic dysfunction includes inhibitors of the renin–angiotensin axis such as angiotensin-converting enzyme inhibitors or angiotensin receptor blockers, angiotensin receptor–neprilysin inhibitors where appropriate, beta-adrenergic blockers, mineralocorticoid receptor antagonists, and sodium–glucose cotransporter 2 inhibitors. Device-based strategies encompass implantable cardioverter–defibrillators for primary prevention of sudden cardiac death, cardiac resynchronization therapy for selected conduction delay, and mechanical circulatory support such as left ventricular assist devices as bridge or destination therapy. Revascularization by percutaneous coronary intervention or coronary artery bypass grafting benefits ischemic etiologies. Valvular repair or replacement addresses severe valvulopathy. Advanced care includes heart transplantation and palliative strategies coordinated by heart failure clinics, nurse-led programs, and multidisciplinary teams.

Prognosis and Epidemiology

Prognosis varies with etiology, functional class, comorbid conditions, and timeliness of treatment; morbidity and mortality remain substantial despite therapeutic advances. Hospital readmission rates are high, and survival declines with progressive New York Heart Association class and recurrent decompensations. Prevalence rises with population aging and the global burden of ischemic heart disease, hypertension, and diabetes, producing significant healthcare utilization and costs. Risk scores and registries inform outcomes and guide allocation of advanced therapies.

Category:Cardiovascular diseases